Key statistics
On Friday, Amarin Corporation PLC (AMRN:NMQ) closed at 0.5486, 20.18% above the 52 week low of 0.4565 set on Nov 18, 2024.
52-week range
Open | 0.530 |
---|---|
High | 0.56 |
Low | 0.5205 |
Bid | 0.5361 |
Offer | 0.5501 |
Previous close | 0.5249 |
Average volume | 1.75m |
---|---|
Shares outstanding | 411.34m |
Free float | 381.31m |
P/E (TTM) | -- |
Market cap | 215.91m USD |
EPS (TTM) | -0.0959 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 21:00 GMT.
More ▼
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual Scientific Sessions
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
- Amarin Announces Two Upcoming Investor Events
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) Meeting
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
- Amarin Board of Directors Announces CEO Transition
More ▼